---
reference_id: "PMID:40023845"
title: The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.
authors:
- Berry D
- Moldoveanu D
- Rajkumar S
- Lajoie M
- Lin T
- Tchelougou D
- Sakthivel S
- Sharon I
- Bernard A
- Pelletier S
- Ripstein Y
- Spatz A
- Miller WH
- Jamal R
- Lapointe R
- Mes-Masson AM
- Petrecca K
- Meguerditchian AN
- Richardson K
- Wang B
- Chergui M
- Guiot MC
- Watters K
- Stagg J
- Schmeing TM
- Rodier F
- Turcotte S
- Mihalcioiu C
- Meterissian S
- Watson IR
journal: Cell Rep
year: '2025'
doi: 10.1016/j.celrep.2025.115365
content_type: abstract_only
---

# The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.
**Authors:** Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, Sakthivel S, Sharon I, Bernard A, Pelletier S, Ripstein Y, Spatz A, Miller WH, Jamal R, Lapointe R, Mes-Masson AM, Petrecca K, Meguerditchian AN, Richardson K, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Schmeing TM, Rodier F, Turcotte S, Mihalcioiu C, Meterissian S, Watson IR
**Journal:** Cell Rep (2025)
**DOI:** [10.1016/j.celrep.2025.115365](https://doi.org/10.1016/j.celrep.2025.115365)

## Content

1. Cell Rep. 2025 Mar 25;44(3):115365. doi: 10.1016/j.celrep.2025.115365. Epub
2025  Mar 1.

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

Berry D(1), Moldoveanu D(2), Rajkumar S(1), Lajoie M(3), Lin T(1), Tchelougou 
D(4), Sakthivel S(1), Sharon I(5), Bernard A(6), Pelletier S(6), Ripstein Y(7), 
Spatz A(8), Miller WH(9), Jamal R(6), Lapointe R(10), Mes-Masson AM(4), Petrecca 
K(11), Meguerditchian AN(12), Richardson K(12), Wang B(12), Chergui M(12), Guiot 
MC(12), Watters K(12), Stagg J(4), Schmeing TM(5), Rodier F(13), Turcotte S(4), 
Mihalcioiu C(12), Meterissian S(12), Watson IR(14).

Author information:
(1)Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC 
H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC H3G 
1Y6, Canada.
(2)Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC 
H3A 1A3, Canada; McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
(3)Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC 
H3A 1A3, Canada.
(4)Centre de Recherche du Centre Hospitalier de l'Université de Montréal 
(CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada; 
Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, 
QC H3T 1J4, Canada.
(5)Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada.
(6)Centre de Recherche du Centre Hospitalier de l'Université de Montréal 
(CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada.
(7)Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada.
(8)McGill University Health Centre, Montréal, QC H4A 3J1, Canada; Lady Davis 
Institute, McGill University, Montréal, QC H3T 1E1, Canada.
(9)Lady Davis Institute, McGill University, Montréal, QC H3T 1E1, Canada.
(10)Centre de Recherche du Centre Hospitalier de l'Université de Montréal 
(CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada; 
Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, 
QC H3T 1J4, Canada; Montreal Neurological Institute and Hospital, Montréal, QC 
H3A 2B4, Canada.
(11)Montreal Neurological Institute and Hospital, Montréal, QC H3A 2B4, Canada.
(12)McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
(13)Centre de Recherche du Centre Hospitalier de l'Université de Montréal 
(CRCHUM) and Institut du cancer de Montréal, Montréal, QC H2X 0A9, Canada; 
Department of Radiology, Radio-Oncology and Nuclear Medicine, Université de 
Montréal, Montreal, QC H3T 1J4, Canada.
(14)Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, 
QC H3A 1A3, Canada; Department of Biochemistry, McGill University, Montréal, QC 
H3G 1Y6, Canada; McGill University Health Centre, Montréal, QC H4A 3J1, Canada. 
Electronic address: ian.watson2@mcgill.ca.

Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in 
approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared 
to mutant BRAF and NRAS, the role of NF1 loss in melanoma remains understudied. 
NF1 has a RAS GTPase-activating protein (GAP) function; however, studies also 
support NF1 RAS-independent tumor-suppressor functions. Recent reports indicate 
that patients with NF1 mutant melanoma have high response rates to anti-PD-1 
immune checkpoint inhibitors (ICIs) for reasons that are not entirely clear. 
Here, we present data demonstrating that NF1 interacts with PD-L1. Furthermore, 
NF1 loss in melanoma lines increases PD-L1 cell surface expression through a 
RAS-GAP-independent mechanism. Co-culture experiments demonstrate that NF1 
depletion in melanoma increases resistance to T cell killing, which can be 
abrogated with anti-PD-1/PD-L1 ICIs. These results support a model whereby NF1 
loss leads to immune evasion through the PD-L1/PD-1 axis, providing support for 
the examination of anti-PD-1 therapies in other NF1 mutant cancers.

Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

DOI: 10.1016/j.celrep.2025.115365
PMID: 40023845 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests The authors declare no 
competing interests related to this study.